These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1676829)

  • 1. Pharmacological profile of non-hydroxylated and ether derivatives of the potent D2-selective agonist N-0437.
    Jansen JM; den Daas I; Rollema H; Swart PJ; Tepper PG; de Vries JB; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Feb; 343(2):134-42. PubMed ID: 1676829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studied by brain dialysis.
    Timmerman W; Tepper PG; Dijkstra D; Stoelwinder H; Grol CJ; Westerink BH; Horn AS
    Eur J Pharmacol; 1991 Jun; 199(2):145-51. PubMed ID: 1683287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal administration of the dopamine agonist N-0437 and seven ester prodrugs: comparison with oral administration in the 6-OHDA turning model.
    den Daas I; Tepper PG; Rollema H; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):655-9. PubMed ID: 1982894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.
    Van der Weide J; De Vries JB; Tepper PG; Krause DN; Dubocovich ML; Horn AS
    Eur J Pharmacol; 1988 Mar; 147(2):249-58. PubMed ID: 3130270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
    Belluzzi JD; Domino EF; May JM; Bankiewicz KS; McAfee DA
    Mov Disord; 1994 Mar; 9(2):147-54. PubMed ID: 7910948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioreceptor binding reveals the potencies of N,N-disubstituted 2-aminotetralins as D2 dopamine agonists.
    Beart PM; Cook CJ; Cincotta M; de Vries DJ; Tepper P; Dijkstra D; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):487-93. PubMed ID: 2963964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic eticlopride and dopamine denervation induce equal nonadditive increases in striatal D2 receptor density: autoradiographic evidence against the dual mechanism hypothesis.
    LaHoste GJ; Marshall JF
    Neuroscience; 1991; 41(2-3):473-81. PubMed ID: 1678501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin (N-0923), a selective D2 dopamine receptor agonist demonstrates the presence of D2 dopamine receptors in the mouse vas deferens but not in the rat vas deferens.
    Martin PL; Kelly M; Cusack NJ
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1342-8. PubMed ID: 7903387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of the calcium content infused during microdialysis for the effects induced by D2 agonists on the release of dopamine in the striatum of the rat.
    Timmerman W; Westerink BH
    Neurosci Lett; 1991 Sep; 131(1):93-6. PubMed ID: 1686479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of kainic acid and 6-hydroxydopamine lesions, metal ions and GTP on in vitro binding of the D-2 dopamine agonist, [3H]N-0437, to striatal membranes.
    Van der Weide J; De Vries JB; Tepper PG; Horn AS
    Eur J Pharmacol; 1987 Nov; 143(1):101-7. PubMed ID: 3121365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic cocaine treatment impairs the regulation of synaptosomal 3H-DA release by D2 autoreceptors.
    Yi SJ; Johnson KM
    Pharmacol Biochem Behav; 1990 Jul; 36(3):457-61. PubMed ID: 1974064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of amphetamine-induced rotation in rats with unilateral intrastriatal grafts of embryonic dopaminergic neurons: a pharmacological and biochemical analysis.
    Herman JP; Rouge-Pont F; Le Moal M; Abrous DN
    Neuroscience; 1993 Apr; 53(4):1083-95. PubMed ID: 8099430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study.
    Savasta M; Mennicken F; Chritin M; Abrous DN; Feuerstein C; Le Moal M; Herman JP
    Neuroscience; 1992; 46(3):729-38. PubMed ID: 1532053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats.
    Santiago M; Westerink BH
    J Neurochem; 1991 Sep; 57(3):738-47. PubMed ID: 1677674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex prejunctional actions of the D2 dopamine agonists N-0923 and N-0924 in the rat tail artery.
    Friedman DJ; Krause DN; Duckles SP
    J Pharmacol Exp Ther; 1992 Feb; 260(2):568-75. PubMed ID: 1346636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pertussis toxin on caudate neuron electrophysiology: studies with dopamine D1 and D2 agonists.
    Bickford-Wimer P; Kim M; Boyajian C; Cooper DM; Freedman R
    Brain Res; 1990 Nov; 533(2):263-7. PubMed ID: 1981169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
    Vermue NA; Kaptein B; Tepper PG; de Vries JB; Horn AS
    Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
    Fenu S; Espa E; Pisanu A; Di Chiara G
    Eur J Pharmacol; 2016 Oct; 788():183-191. PubMed ID: 27343381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.